{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MPN",
    "query": {
      "condition": "MPN"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 84,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MPN&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:30:27.710Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02587598",
      "title": "Study of INCB053914 in Subjects With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB053914",
          "type": "DRUG"
        },
        {
          "name": "I-DAC (Intermediate dose cytarabine)",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2015-12-29",
      "completion_date": "2020-08-11",
      "has_results": true,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Sacramento, California • Santa Monica, California + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587598"
    },
    {
      "nct_id": "NCT04061421",
      "title": "Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "MDS/MPN"
      ],
      "interventions": [
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Savona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2021-11-24",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04061421"
    },
    {
      "nct_id": "NCT02252159",
      "title": "Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2544,
      "start_date": "2014-07-31",
      "completion_date": "2019-08-03",
      "has_results": false,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 264,
      "location_summary": "Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more",
      "locations": [
        {
          "city": "Green Valley",
          "state": "Arizona"
        },
        {
          "city": "Safford",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252159"
    },
    {
      "nct_id": "NCT05482971",
      "title": "A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Thrombocythemia"
      ],
      "interventions": [
        {
          "name": "Ropeginterferon alfa-2b-njft (P1101)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaEssentia",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2022-09-29",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482971"
    },
    {
      "nct_id": "NCT00509106",
      "title": "Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil for Injection",
          "type": "DRUG"
        },
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 622,
      "start_date": "2007-07",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-14",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509106"
    },
    {
      "nct_id": "NCT04605211",
      "title": "A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Online Mindfulness Meditation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Internet-Based Webinars",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2020-09-18",
      "completion_date": "2022-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605211"
    },
    {
      "nct_id": "NCT02493530",
      "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis",
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "TGR-1202",
          "type": "DRUG"
        },
        {
          "name": "ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2015-07",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02493530"
    },
    {
      "nct_id": "NCT01393509",
      "title": "The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Lymphoma",
        "Myeloproliferative Neoplasms (MPN)"
      ],
      "interventions": [
        {
          "name": "PU-H71",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2011-07-06",
      "completion_date": "2023-03-23",
      "has_results": false,
      "last_update_posted_date": "2023-03-28",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01393509"
    },
    {
      "nct_id": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasm",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "PRT1419",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-03-22",
      "completion_date": "2024-01-19",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 9,
      "location_summary": "Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more",
      "locations": [
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Brick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107856"
    },
    {
      "nct_id": "NCT03755518",
      "title": "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-Polycythemia Vera Myelofibrosis",
        "Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "FEDRATINIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-03-27",
      "completion_date": "2023-11-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-05-22T05:30:27.710Z",
      "location_count": 28,
      "location_summary": "Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755518"
    }
  ]
}